Voyager Therapeutics, Inc. (VYGR) company profile
Close on Nov 13, 2026Market cap $106.60MP/E –Yield –
About Voyager Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Voyager Therapeutics is a biotechnology company focused on developing therapies for severe neurological conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and Friedreich's ataxia. The company develops intravenous gene therapies and antibody treatments utilizing its proprietary TRACER adeno-associated virus capsid discovery platform and NeuroShuttle delivery system, which facilitate transport across the blood-brain barrier. Its pipeline consists of wholly owned drug candidates, such as tau-directed programs for Alzheimer's disease, as well as partnered programs. Its customers and commercial partners include global pharmaceutical and biotechnology corporations such as Novartis, Neurocrine Biosciences, and Alexion, which license Voyager's capsids and collaborate on research, development, and potential commercialization.
The provided text does not state the location of the company's headquarters, its facility count, or its employee numbers. Geographically, the company's collaborative agreements and licensing frameworks encompass operations in the United States and key international markets, including the United Kingdom, France, Germany, Italy, Spain, and Japan, alongside worldwide development and commercialization rights.
Summary of the business section of Voyager Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Voyager Therapeutics, Inc.
- Founded
- 2013
- Headquarters
- Lexington, MA
- Address
- 75 Hayden Avenue 02421
- Phone
- (857) 259-5340
- Website
- www.voyagertherapeutics.com
- Employees
- 141, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- VYGR
- Exchange
- Nasdaq
- IPO date
- Nov 12, 2015
- Shares outstanding
- 62M, Jul 30, 2026
- Public float
- $144.20M, Jun 30, 2025
- Filer category
- Accelerated filer<br>Smaller reporting company
- SEC CIK
- 1640266
- CUSIP
- 92915B106
- ISIN
- US92915B1061
- FIGI
- BBG005ZSY233
- Share class FIGI
- BBG005ZSY242
- LEI
- 54930082S4XVR0ZWCC74
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Alfred Sandrock | President and CEO, Director | 472,549 |
| Robin Swartz | President | 267,988 |
| Todd Alfred Carter | Chief Scientific Officer | 178,718 |
| Amy Quinlan | Principal Accounting Officer | 36,749 |
| Gregory L. Shiferman | SVP and General Counsel | 50,000 |
| Nathan D. Jorgensen | Chief Financial Officer | 151,416 |
| Toby Ferguson | Chief Medical Officer | 183,914 |
| Sandell Jacquelyn Fahey | Chief Legal Officer | 123,143 |
| Catherine J. Mackey | Director | – |
| Nancy Vitale | Director | – |
| James A. Geraghty | Director | 76,588 |
| George A. Scangos | Director | – |
| Michael J. Higgins | Director | 31,314 |
| Steven Hyman | Director | – |
| Glenn Pierce | Director | 21,788 |
| Grace Colon | Director | – |
| Jude Onyia | Director | 2,910 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $2.51M | $2.05M | $1.43M | $64 | – |
| FY2024 Alfred Sandrock | $3.38M | $888.93K | $2.42M | $93 | – |
| FY2024 Dr.Sandrock | $3.38M | $891.41K | $2.42M | $93 | – |
| FY2023 | $3.17M | $5.14M | $1.53M | $138 | – |
| FY2022 Alfred Sandrock | $7.41M | $5.39M | $1.35M | $225 | – |
| FY2022 Michael Higgins | $757.53K | $1.38M | $1.35M | $225 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | $674.90K | $611.90K | $843.90K | $361.92K | $15.75K | $2.51M | -26% |
| Jacquelyn Fahey Sandell Former Chief Legal Officer | $297.84K | $175.13K | $241.53K | – | $760.48K | $1.47M | +20% |
| Robin Swartz Chief Business Officer & Chief Operating Officer | $520.19K | $300.68K | $414.68K | $205.48K | $13.29K | $1.45M | -10% |
| Toby Ferguson, M.D., Ph.D. Former Chief Medical Officer | $513.37K | $265.86K | $366.66K | $202.78K | $15.75K | $1.36M | -54% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 12, 2015
- Offer price
- $14.00
- Securities offered
- 5,000,000
- Gross proceeds
- $70.00M
- Exchange
- Nasdaq
- First trading day
- Nov 11, 2015
- First-day close
- $17.75+26.8%
- Lock-up ends (est.)
- May 9, 2016
“Per Share Total Initial public offering price $14.00 $70,000,000 Underwriting discounts and commissions (1) $ 0.98 $ 4,900,000 Proceeds, before expenses, to Voyager $13.02 $65,100,000 (1) We refer you to the section titled "Underwriting" beginning on page 169 for additional information regarding total underwriting”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 141 full-time employees in the United States, including 112 in research and development positions and 29 in general and administrative positions.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 5, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 12, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 6, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?